Details of the Drug

General Information of Drug (ID: DM3NXRU)

Drug Name
Timolol
Synonyms
Aquanil; Betim; Betimol; Blocadren; Istalol; Optimol; Proflax; TIM; Temserin; Tenopt; Timacar; Timololum; Timopic; Timoptol; Timolol GFS; Timolol [USAN]; Timoptic OcuDose; Apo-Timol; Apo-Timop; Betimol (TN); Blocadren (TN); Istalol (TN); MK-950; Novo-Timol; Nu-Timolol; Phoxal-timolol; Tim-AK; Timolol (INN); Timolol (TN); Timololum [INN-Latin]; Timoptic (TN); Timoptic-XE; Apo-Timol (TN); Apo-Timop (TN); Gen-Timolol (TN); L-714,465; Nu-Timolol (TN); PMS-Timolol (TN); Phoxal-timolol (TN); Tim-AK (TN); Timoptic OcuDose. (TN); Timoptic-XE (TN); S(-)-Timolol maleate; Timolol Maleate, (1:1) Salt; S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole; (-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole; (2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol; (S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol; (S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol; (S)-timolol
Indication
Disease Entry ICD 11 Status REF
High blood pressure BA00 Approved [1]
Ocular hypertension 9C61.01 Approved [2]
Therapeutic Class
Antiarrhythmic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 316.42
Logarithm of the Partition Coefficient (xlogp) 1.8
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 6.46 mcgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 1.14 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 15 min [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 78.0 +/- 24.5% [3]
Clearance
The renal clearance of drug is 97.2 +/- 10.1 mL/min [5]
Elimination
15% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.9 +/- 0.3 hours [6]
Metabolism
The drug is metabolized via the liver [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.1603 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.9% [8]
Vd
The volume of distribution (Vd) of drug is 1.3-1.7 L/kg [9]
Water Solubility
The ability of drug to dissolve in water is measured as 2.74 mg/mL [4]
Chemical Identifiers
Formula
C13H24N4O3S
IUPAC Name
(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
Canonical SMILES
CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O
InChI
InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1
InChIKey
BLJRIMJGRPQVNF-JTQLQIEISA-N
Cross-matching ID
PubChem CID
33624
ChEBI ID
CHEBI:9599
CAS Number
26839-75-8
DrugBank ID
DB00373
TTD ID
D05UVD
VARIDT ID
DR00900
INTEDE ID
DR1595
ACDINA ID
D00677
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Antagonist [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [12]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [13]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Drug Response [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Timolol
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ethacrynic acid DM60QMR Moderate Increased risk of hypertriglyceridemia by the combination of Timolol and Ethacrynic acid. Essential hypertension [BA00] [15]
Bendroflumethiazide DM7EVLC Moderate Increased risk of hyperglycemia by the combination of Timolol and Bendroflumethiazide. Essential hypertension [BA00] [15]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Timolol and Phenoxybenzamine. Essential hypertension [BA00] [16]
Nicardipine DMCDYW7 Moderate Increased risk of cardiac depression by the combination of Timolol and Nicardipine. Essential hypertension [BA00] [17]
Benzthiazide DMQWZ0H Moderate Increased risk of ventricular arrhythmias by the combination of Timolol and Benzthiazide. Essential hypertension [BA00] [15]
Coadministration of a Drug Treating the Disease Different from Timolol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Scopolamine DMOM8AL Moderate Antagonize the effect of Timolol when combined with Scopolamine. Addictive disorder [6C50-6C5Z] [18]
Tripelennamine DMZBU15 Moderate Decreased metabolism of Timolol caused by Tripelennamine mediated inhibition of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [19]
Bepridil DM0RKS4 Moderate Increased risk of cardiac depression by the combination of Timolol and Bepridil. Angina pectoris [BA40] [17]
Dronedarone DMA8FS5 Moderate Increased risk of bradycardia by the combination of Timolol and Dronedarone. Angina pectoris [BA40] [20]
Nifedipine DMSVOZT Moderate Increased risk of cardiac depression by the combination of Timolol and Nifedipine. Angina pectoris [BA40] [17]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Timolol caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [21]
Promazine DMZAL7W Moderate Additive hypotensive effects by the combination of Timolol and Promazine. Appearance/behaviour symptom [MB23] [22]
Zileuton DMVRIC2 Moderate Decreased metabolism of Timolol caused by Zileuton. Asthma [CA23] [23]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Timolol and Cariprazine. Bipolar disorder [6A60] [22]
Secobarbital DM14RF5 Moderate Increased metabolism of Timolol caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [24]
Atracurium DM42HXN Moderate Additive neuromuscular blocking effects by the combination of Timolol and Atracurium. Corneal disease [9A76-9A78] [25]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Timolol and Mivacurium. Corneal disease [9A76-9A78] [25]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Timolol and Pancuronium. Corneal disease [9A76-9A78] [25]
Tubocurarine DMBZIVP Moderate Additive neuromuscular blocking effects by the combination of Timolol and Tubocurarine. Corneal disease [9A76-9A78] [25]
Nimodipine DMQ0RKZ Moderate Increased risk of cardiac depression by the combination of Timolol and Nimodipine. Coronary vasospastic disease [BA85] [17]
Pasireotide DMHM7JS Moderate Increased risk of atrioventricular block by the combination of Timolol and Pasireotide. Cushing syndrome [5A70] [26]
Sertraline DM0FB1J Moderate Decreased metabolism of Timolol caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [27]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Timolol caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [27]
Paroxetine DM5PVQE Moderate Decreased metabolism of Timolol caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [27]
Duloxetine DM9BI7M Moderate Decreased metabolism of Timolol caused by Duloxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [28]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Timolol and OPC-34712. Depression [6A70-6A7Z] [22]
Hyoscyamine DM804UR Moderate Antagonize the effect of Timolol when combined with Hyoscyamine. Digestive system disease [DE2Z] [29]
Mepenzolate DM8YU2F Moderate Antagonize the effect of Timolol when combined with Mepenzolate. Digestive system disease [DE2Z] [18]
Oxybutynine DMJPBAX Moderate Antagonize the effect of Timolol when combined with Oxybutynine. Discovery agent [N.A.] [18]
Trihexyphenidyl DMB19L8 Moderate Antagonize the effect of Timolol when combined with Trihexyphenidyl. Dystonic disorder [8A02] [18]
Fenfluramine DM0762O Moderate Decreased metabolism of Timolol caused by Fenfluramine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [19]
Primidone DM0WX6I Moderate Increased metabolism of Timolol caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [24]
Stiripentol DMMSDOY Moderate Decreased metabolism of Timolol caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Phenobarbital DMXZOCG Moderate Increased metabolism of Timolol caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [24]
Diphenhydramine DMKQTBA Moderate Decreased metabolism of Timolol caused by Diphenhydramine mediated inhibition of CYP450 enzyme. Episodic vestibular syndrome [AB31] [19]
Phenylephrine DMZHUO5 Moderate Additive hypertensive effects by the combination of Timolol and Phenylephrine. Faecal incontinence [ME07] [31]
Mirabegron DMS1GYT Moderate Decreased metabolism of Timolol caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [32]
Tolterodine DMSHPW8 Moderate Antagonize the effect of Timolol when combined with Tolterodine. Functional bladder disorder [GC50] [18]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Timolol caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [33]
Terbinafine DMI6HUW Moderate Decreased metabolism of Timolol caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [34]
Propantheline DM2EN6G Moderate Additive CNS depression effects by the combination of Timolol and Propantheline. Gastric ulcer [DA60] [29]
Cimetidine DMH61ZB Moderate Decreased metabolism of Timolol caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [35]
Spironolactone DM2AQ5N Moderate Increased risk of hypertriglyceridemia by the combination of Timolol and Spironolactone. Heart failure [BD10-BD1Z] [15]
Triamterene DM2HU9I Moderate Increased risk of hypertriglyceridemia by the combination of Timolol and Triamterene. Heart failure [BD10-BD1Z] [15]
Prazosin DMCD9YG Moderate Additive hypotensive effects by the combination of Timolol and Prazosin. Heart failure [BD10-BD1Z] [16]
Chlorothiazide DMLHESP Moderate Increased risk of hyperglycemia by the combination of Timolol and Chlorothiazide. Heart failure [BD10-BD1Z] [15]
Furosemide DMMQ8ZG Moderate Increased risk of hypertriglyceridemia by the combination of Timolol and Furosemide. Heart failure [BD10-BD1Z] [15]
Bumetanide DMRV7H0 Moderate Increased risk of hypertriglyceridemia by the combination of Timolol and Bumetanide. Heart failure [BD10-BD1Z] [15]
Hydroflumethiazide DMVPUQI Moderate Increased risk of hyperglycemia by the combination of Timolol and Hydroflumethiazide. Heart failure [BD10-BD1Z] [15]
Rifampin DMA8J1G Moderate Increased metabolism of Timolol caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [36]
Delavirdine DM3NF5G Moderate Decreased metabolism of Timolol caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [19]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Timolol caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Ritonavir DMU764S Moderate Decreased metabolism of Timolol caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Timolol caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [29]
Nisoldipine DM7ISKJ Moderate Increased risk of cardiac depression by the combination of Timolol and Nisoldipine. Hypertension [BA00-BA04] [17]
Levamlodipine DM92S6N Moderate Increased risk of cardiac depression by the combination of Timolol and Levamlodipine. Hypertension [BA00-BA04] [17]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Timolol and Doxazosin. Hypertension [BA00-BA04] [16]
Verapamil DMA7PEW Major Increased risk of cardiac depression by the combination of Timolol and Verapamil. Hypertension [BA00-BA04] [17]
Amlodipine DMBDAZV Moderate Increased risk of cardiac depression by the combination of Timolol and Amlodipine. Hypertension [BA00-BA04] [17]
Indapamide DMGN1PW Moderate Increased risk of hypertriglyceridemia by the combination of Timolol and Indapamide. Hypertension [BA00-BA04] [15]
Trichlormethiazide DMHAQCO Moderate Increased risk of hypertriglyceridemia by the combination of Timolol and Trichlormethiazide. Hypertension [BA00-BA04] [15]
Felodipine DMOSW35 Moderate Increased risk of cardiac depression by the combination of Timolol and Felodipine. Hypertension [BA00-BA04] [17]
Hydralazine DMU8JGH Minor Decreased metabolism of Timolol caused by Hydralazine mediated interference with first-pass metabolism. Hypertension [BA00-BA04] [39]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of hyperglycemia by the combination of Timolol and Hydrochlorothiazide. Hypertension [BA00-BA04] [15]
Clevidipine butyrate DMW4M97 Moderate Increased risk of cardiac depression by the combination of Timolol and Clevidipine butyrate. Hypertension [BA00-BA04] [17]
Givosiran DM5PFIJ Moderate Decreased metabolism of Timolol caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [40]
Belladonna DM2RBWK Moderate Antagonize the effect of Timolol when combined with Belladonna. Infectious gastroenteritis/colitis [1A40] [18]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Timolol caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [41]
Amobarbital DM0GQ8N Moderate Increased metabolism of Timolol caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [24]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Timolol and Propiomazine. Insomnia [7A00-7A0Z] [22]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Timolol and ITI-007. Insomnia [7A00-7A0Z] [22]
Clidinium DMUMQZ0 Moderate Antagonize the effect of Timolol when combined with Clidinium. Irritable bowel syndrome [DD91] [18]
Dicyclomine DMZSDGX Moderate Antagonize the effect of Timolol when combined with Dicyclomine. Irritable bowel syndrome [DD91] [18]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Timolol caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [18]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Timolol caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [42]
Lumefantrine DM29GAD Moderate Decreased metabolism of Timolol caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [29]
Halofantrine DMOMK1V Moderate Decreased metabolism of Timolol caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [19]
Chloroquine DMSI5CB Minor Decreased metabolism of Timolol caused by Chloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [43]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Timolol caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [19]
Quinine DMSWYF5 Moderate Decreased metabolism of Timolol caused by Quinine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [19]
Primaquine DMWQ16I Moderate Decreased metabolism of Timolol caused by Primaquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [19]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Timolol caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [44]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Timolol due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [26]
Panobinostat DM58WKG Moderate Decreased metabolism of Timolol caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [45]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Timolol and Thalidomide. Multiple myeloma [2A83] [29]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Timolol and Siponimod. Multiple sclerosis [8A40] [29]
Fingolimod DM5JVAN Major Increased risk of atrioventricular block by the combination of Timolol and Fingolimod. Multiple sclerosis [8A40] [46]
Ozanimod DMT6AM2 Moderate Increased risk of bradycardia by the combination of Timolol and Ozanimod. Multiple sclerosis [8A40] [47]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Timolol caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [18]
Imatinib DM7RJXL Moderate Decreased metabolism of Timolol caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [48]
Prochlorperazine DM53SRA Moderate Additive hypotensive effects by the combination of Timolol and Prochlorperazine. Nausea/vomiting [MD90] [22]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Timolol and Promethazine. Nausea/vomiting [MD90] [22]
Rolapitant DM8XP26 Moderate Decreased metabolism of Timolol caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [49]
Cyclizine DM9G7BS Moderate Decreased metabolism of Timolol caused by Cyclizine mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [19]
Metoclopramide DMFA5MY Moderate Decreased metabolism of Timolol caused by Metoclopramide mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [19]
Bupropion DM5PCS7 Moderate Decreased metabolism of Timolol caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [50]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Timolol caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [51]
Dexfenfluramine DMJ7YDS Moderate Decreased metabolism of Timolol caused by Dexfenfluramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [19]
Metolazone DMB39LO Moderate Increased risk of ventricular arrhythmias by the combination of Timolol and Metolazone. Oedema [MG29] [15]
Polythiazide DMCH80F Moderate Increased risk of hypertriglyceridemia by the combination of Timolol and Polythiazide. Oedema [MG29] [15]
Dextropropoxyphene DM23HCX Moderate Decreased metabolism of Timolol caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [52]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Timolol and Biperiden. Parkinsonism [8A00] [18]
Procyclidine DMHFJDT Moderate Additive CNS depression effects by the combination of Timolol and Procyclidine. Parkinsonism [8A00] [18]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Timolol caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [53]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Timolol and Terazosin. Prostate hyperplasia [GA90] [16]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Timolol and Silodosin. Prostate hyperplasia [GA90] [16]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Timolol and Levomepromazine. Psychotic disorder [6A20-6A25] [22]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Timolol and Fluphenazine. Psychotic disorder [6A20-6A25] [22]
Celecoxib DM6LOQU Moderate Decreased metabolism of Timolol caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [54]
Oxamniquine DM2QDX1 Moderate Decreased metabolism of Timolol caused by Oxamniquine mediated inhibition of CYP450 enzyme. Schistosomiasis [1F86] [19]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Timolol and Quetiapine. Schizophrenia [6A20] [22]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Timolol and Mesoridazine. Schizophrenia [6A20] [22]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Timolol and Thioridazine. Schizophrenia [6A20] [22]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Timolol and Aripiprazole. Schizophrenia [6A20] [22]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Timolol and Iloperidone. Schizophrenia [6A20] [22]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Timolol and Paliperidone. Schizophrenia [6A20] [22]
Loxapine DM8AI9U Moderate Additive hypotensive effects by the combination of Timolol and Loxapine. Schizophrenia [6A20] [22]
Haloperidol DM96SE0 Moderate Additive hypotensive effects by the combination of Timolol and Haloperidol. Schizophrenia [6A20] [22]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Timolol and Perphenazine. Schizophrenia [6A20] [22]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Timolol and Molindone. Schizophrenia [6A20] [22]
Chlorpromazine DMBGZI3 Moderate Additive hypotensive effects by the combination of Timolol and Chlorpromazine. Schizophrenia [6A20] [22]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Timolol and Thiothixene. Schizophrenia [6A20] [22]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Timolol and Trifluoperazine. Schizophrenia [6A20] [22]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Timolol and Risperidone. Schizophrenia [6A20] [22]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Timolol and Amisulpride. Schizophrenia [6A20] [18]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Timolol and Asenapine. Schizophrenia [6A20] [22]
Pipecuronium DM5F84A Moderate Additive neuromuscular blocking effects by the combination of Timolol and Pipecuronium. Tonus and reflex abnormality [MB47] [25]
Doxacurium DMKE7L9 Moderate Additive neuromuscular blocking effects by the combination of Timolol and Doxacurium. Tonus and reflex abnormality [MB47] [25]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Timolol and Vecuronium. Tonus and reflex abnormality [MB47] [25]
Cisatracurium DMUZPJ5 Moderate Additive neuromuscular blocking effects by the combination of Timolol and Cisatracurium. Tonus and reflex abnormality [MB47] [25]
Rocuronium DMY9BMK Moderate Additive neuromuscular blocking effects by the combination of Timolol and Rocuronium. Tonus and reflex abnormality [MB47] [25]
Atropine DMEN6X7 Moderate Antagonize the effect of Timolol when combined with Atropine. Unspecific substance harmful effect [NE6Z] [18]
Chlorpheniramine DM5URA2 Moderate Decreased metabolism of Timolol caused by Chlorpheniramine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [19]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Timolol and Methdilazine. Vasomotor/allergic rhinitis [CA08] [22]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Timolol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [55]
Propafenone DMPIBJK Moderate Decreased metabolism of Timolol caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [56]
Amiodarone DMUTEX3 Moderate Increased risk of bradycardia by the combination of Timolol and Amiodarone. Ventricular tachyarrhythmia [BC71] [57]
⏷ Show the Full List of 132 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Benzalkonium chloride E00536 21988052 Antimicrobial preservative; Penetration agent; Solubilizing agent; Surfactant
Carmellose sodium E00625 Not Available Disintegrant
Disodium hydrogenorthophosphate E00283 24203 Buffering agent; Complexing agent
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Water E00035 962 Solvent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Timolol 10 mg tablet 10 mg Oral Tablet Oral
Timolol 20 mg tablet 20 mg Oral Tablet Oral
Timolol 5 mg tablet 5 mg Oral Tablet Oral
Timolol Maleate eq 0.25% base solution eq 0.25% base Solution Ophthalmic
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 565).
2 Timolol FDA Label
3 Korte JM, Kaila T, Saari KM: Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol. 2002 Jun;240(6):430-5. doi: 10.1007/s00417-002-0462-2. Epub 2002 Apr 26.
4 BDDCS applied to over 900 drugs
5 Ishizaki T, Tawara K, Oyama Y, Nakaya H: Clinical pharmacologic observations on timolol. I. Disposition and effect in relation to plasma level in normal individuals. J Clin Pharmacol. 1978 Nov-Dec;18(11-12):511-8.
6 Pharmacokinetic interactions of timolol with vasodilating drugs, food and phenobarbitone in healthy human volunteers. Eur J Clin Pharmacol. 1983;24(2):227-30.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
9 Link
10 Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
11 Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11.
12 Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016 Nov;15(11):1549-1561.
13 Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011 May;108(5):297-303.
14 Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol. J Ocul Pharmacol Ther. 2009 Apr;25(2):163-71. doi: 10.1089/jop.2008.0028.
15 Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
16 Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
17 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
18 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19 Edeki TI, He HB, Wood AJJ "Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction." JAMA 274 (1995): 1611-3. [PMID: 7474246]
20 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
21 Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C "Influence of pentobarbital on metoprolol plasma levels." Clin Pharmacol Ther 26 (1979): 326-9. [PMID: 466926]
22 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
23 Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
24 Branch RA, Herman RJ "Enzyme induction and beta-adrenergic receptor blocking drugs." Br J Clin Pharmacol 17 (1984): s77-84. [PMID: 6146342]
25 Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
26 Canadian Pharmacists Association.
27 Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
28 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
29 Cerner Multum, Inc. "Australian Product Information.".
30 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
31 Cass E, Kadar D, Stein HA "Hazards of phenylephrine topical medication in persons taking propranolol." Can Med Assoc J 120 (1979): 1261-2. [PMID: 221086]
32 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
33 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
34 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
35 Asgharnejad M, Powell R, Donn K, Danis M "The effect of cimetidine dose timing on oral propranolol kinetics in adults." Clin Pharmacol Ther 41 (1987): 203. [PMID: 3392231]
36 Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE "Interaction of bisoprolol with cimetidine and rifampicin." Eur J Clin Pharmacol 31 (1986): 59-62. [PMID: 2877885]
37 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
38 Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
39 Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21. [PMID: 1451723]
40 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
41 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
42 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
43 Lancaster DL, Adio RA, Tai KK, Simooya OO, Broadhead GD, Tucker GT, Lennard MS "Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs." J Pharm Pharmacol 42 (1990): 267-71. [PMID: 1974295]
44 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
45 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
46 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
47 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
48 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
49 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
50 Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541]
51 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
52 Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40. [PMID: 1349528]
53 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
54 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
55 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
56 Ahmad S "Metoprolol-induced delirium perpetuated by propafenone." Am Fam Physician 44 (1991): 1142,4. [PMID: 1927831]
57 Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]